25 August, 2016 by The TZ Newswire Staff Comments Off on Harley-Davidson Inc.: 2 Reasons to Buy, 2 Reasons to Avoid
Harley-Davidson Inc.: 2 Reasons to Buy, 2 Reasons to Avoid
Harley-Davidson faces stiff competition and relatively weak demand growth, but its stock is cheap and its brand is strong. Image source: Getty Images.
25 August, 2016 by The TZ Newswire Staff Comments Off on Iran headed to OPEC meeting in Algeria
Iran headed to OPEC meeting in Algeria
Iranian news agency Shana reports
Iran will join the all-talk-no-action summit in Algeria from September 26-28.
The news is more confirmation than anything. Various reports yesterday and earlier said Iran had booked its ticket.
25 August, 2016 by The TZ Newswire Staff Comments Off on Fed’s Esther George: Interest rates should go higher, but gradually
Fed’s Esther George: Interest rates should go higher, but gradually
Recent economic data have given policymakers pause, says Kansas City Fed’s Esther George.
25 August, 2016 by The TZ Newswire Staff Comments Off on Lawrence G. McMillan: Bulls begin to face questions about further upside
Lawrence G. McMillan: Bulls begin to face questions about further upside
The bullish trend is still in place, but there are potential problems ahead.
25 August, 2016 by The TZ Newswire Staff Comments Off on Fed’s George says it’s time for raising interest rates
Fed’s George says it’s time for raising interest rates
Kansas City Fed Esther George said Thursday it was time to begin raising interest rates.
read more
25 August, 2016 by The TZ Newswire Staff Comments Off on The Wall Street Journal: Mylan expanding eligibility for EpiPen financial assistance after backlash
The Wall Street Journal: Mylan expanding eligibility for EpiPen financial assistance after backlash
Mylan says it’s extending financial assistance to those who use the EpiPen allergy treatment after widespread criticism.
read more
25 August, 2016 by The TZ Newswire Staff Comments Off on Mylan’s EpiPen Price Cut Could Set a Dangerous Biotech Precedent
Mylan’s EpiPen Price Cut Could Set a Dangerous Biotech Precedent
Mylan is cutting the price of its lifesaving EpiPen product for needy users, in a move that could set a big pre